SCHEMBL369528

SCHEMBL369528

C=CC(=O)c1cn(Cc2ccc(OC)cc2)nc1C(C)(C)O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
KLKB1 P03952 9/20 0.42
AADAT Q8N5Z0 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
PDE1A P54750 1/20 0.39
PDE1B Q01064 1/20 0.39
PDE1C Q14123 1/20 0.39
CACNA1G O43497 1/20 0.39
CACNA1H O95180 1/20 0.39
CACNA1I Q9P0X4 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HDAC1 Q13547 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 1/20 0.38
SNCA P37840 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370600 0.82 KLKB1 (0.43) KMT2AKLKB1AADATHSP90AA1HSP90AB1
SCHEMBL6837432 0.79 KMT2A (0.41) KMT2AKLKB1AADATCACNA1GCACNA1H
SCHEMBL370874 0.78 FLT3 (0.42) KMT2AKLKB1AADATCACNA1GCACNA1H
SCHEMBL371196 0.78 PDE1B (0.42) KMT2AKLKB1AADATPDE1BCACNA1G
SCHEMBL370205 0.77 KMT2A (0.40) KMT2AKLKB1AADATCACNA1GCACNA1H
SCHEMBL370630 0.77 PKM (0.41) KMT2AKLKB1AADATCACNA1GCACNA1H
SCHEMBL370519 0.76 CACNA1G (0.41) KMT2AKLKB1AADATCACNA1GCACNA1H
SCHEMBL369527 0.76 AADAT (0.39) KMT2AAADATHSP90AA1HSP90AB1PDE1A
SCHEMBL6837102 0.75 KMT2A (0.51) KMT2AAADATCACNA1GCACNA1HCACNA1I
SCHEMBL15182579 0.75 KMT2A (0.43) KMT2AKLKB1AADATCACNA1GCACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 KMT2A 1638/4885KLKB1 4667/4885AADAT 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.